Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive seizures in epileptics.

Acorda was off $1.07 on the week.

Biota Pharmaceuticals Inc. (NASDAQ:BOTA) fell $1.89 (34%) to $3.68 on Tuesday after reporting that HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) issued a stop-work order for laninamivir octanoate. Biota is developing the influenza product under a BARDA contract worth up to $231 million.

The order is in effect pending a decision from HHS, which the company said it expects "within the next week or so."

Biota lost $1.84 (34%) to $3.59 on the week.

The Medicines Co. (NASDAQ:MDCO) was up $0.41 to $26.46 last week. FDA issued a complete response letter for cangrelor for its two proposed indications: to reduce thrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI); and as bridging therapy for patients with stents who are at increased risk for thrombotic events when oral P2Y12

Read the full 1842 word article

How to gain access

Continue reading with a
two-week free trial.